Pharmaceutical Pricing and Revenue Management

Handle structures pharmaceutical pricing and revenue management for companies operating into and across the UAE; aligning regulatory compliance, access pathways, and commercial discipline into one controlled framework. We lock pricing architecture, contracting structures, and cash flows into strategies that withstand scrutiny from regulators, payors, and institutional capital.

From launch price setting and HTA-driven access to complex rebate models, tender exposure, and revenue leakage recovery, we execute under one mandate. Law to protect, economics to justify, and governance to sustain pricing and revenue decisions at scale.

Pharmaceutical pricing in the UAE and wider GCC is not a pure commercial question. It is a regulated, reference-linked, and politically visible construct that demands legal, economic, and operational control.

Handle integrates regulatory fluency with capital discipline and execution on the ground; we design pricing and revenue structures that stand up to audits, negotiations, and capital due diligence.

• Deep understanding of UAE and GCC pricing frameworks, approvals, and reference dynamics
• Integration of market access, HTA evidence, and commercial contracting into one model
• Structured governance for discounts, rebates, and patient access schemes
• Clear visibility on net revenue, margin, and payor mix across channels
• Revenue integrity programs that detect leakage and enforce corrective action
• Board-ready documentation that withstands regulatory and investor scrutiny

We structure pharmaceutical pricing and revenue management from portfolio strategy to contract execution and monitoring, with clear control points at each stage. Our model covers originators, biosimilars, generics, devices, and specialty therapies entering or expanding through the UAE and regional markets.

Every mandate is engineered for regulatory defensibility, economic clarity, and enforceable commercial terms.

• Portfolio and indication-level pricing strategy aligned with UAE and GCC regulations
• Launch and re-pricing scenarios, including reference price impact and lifecycle management
• Market access and HTA evidence alignment for public and private payors
• Design of discount, rebate, and patient access structures with governance and audit trails
• Tender and institutional contracting frameworks with risk-sharing and performance clauses
• Revenue integrity programs covering data, controls, KPIs, and leakage remediation